US20090068254A1 - Multivalent liposomal vaccine compositions comprising polysaccharide antigens and a protein adjuvant - Google Patents

Multivalent liposomal vaccine compositions comprising polysaccharide antigens and a protein adjuvant Download PDF

Info

Publication number
US20090068254A1
US20090068254A1 US12/088,656 US8865606A US2009068254A1 US 20090068254 A1 US20090068254 A1 US 20090068254A1 US 8865606 A US8865606 A US 8865606A US 2009068254 A1 US2009068254 A1 US 2009068254A1
Authority
US
United States
Prior art keywords
composition
liposomes
polysaccharide
antigen
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/088,656
Other languages
English (en)
Inventor
Andrew David Bacon
Gregory Gregoriadis
Peter Laing
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lipoxen Technologies Ltd
Original Assignee
Lipoxen Technologies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lipoxen Technologies Ltd filed Critical Lipoxen Technologies Ltd
Assigned to LIPOXEN TECHNOLOGIES LIMITED reassignment LIPOXEN TECHNOLOGIES LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BACON, ANDREW DAVID, GREGORIADIS, GREGORY, LAING, PETER
Publication of US20090068254A1 publication Critical patent/US20090068254A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Definitions

  • the present invention relates to liposomal compositions, in particular compositions useful for eliciting an immune response against polysaccharide antigens, in particular derived from pathogenic microbes, such as pneumococcal and Hib polysaccharide antigens.
  • Bacterial infections caused by encapsulated bacteria are a major world health problem.
  • the species Streptococcus pneumoniae, Haemophilus influenzae and Neisseria meningitidis are difficult to vaccinate against due to the thymus independent nature of the major surface antigens, the capsular polysaccharides.
  • T-cell independent antigens present particular problems regarding the development of effective vaccines.
  • Antibody production is low and is not normally boosted by re-immunisation.
  • the antibody isotypes are restricted to IgM and other isotypes are generally of low affinity for a specific antigen.
  • T-cell independent vaccines A major problem lies in the response of young children to T-cell independent vaccines. These individuals are amongst the most vulnerable such bacterial infections. This age group responds most poorly to T-cell independent antigens.
  • polysaccharides have been conjugated to carrier proteins such as tetanus toxoid, which results in some improvement in immunogenic effect.
  • carrier proteins such as tetanus toxoid
  • the polysaccharides have alternatively been formulated with liposomes, which also gives an enhanced immune response.
  • Alpha toxin is a highly toxic substance and is haemolytic. The authors reason that its activity in potentiating the antigenicity of the polysaccharide antigen is dependent upon the properties it exhibits as a toxin involving puncturing of the cell membrane. They show that the potentiation is not achieved with heat inactivated toxin derivative. Alpha toxin has a subunit molecular weight of about 33 kDa.
  • a new liposomal composition comprising two or more polysaccharide antigens and a non-toxic protein carrier having at least one T-cell epitope, wherein each polysaccharide antigen is coentrapped within liposomes with protein carrier and the liposomes are formed of liposome forming compounds comprising at least one phospholipid.
  • the term “coentrapped” means that the two actives, namely the polysaccharide antigen and the protein carrier, must be associated with the same liposome. Although association may be solely with the outer surface of liposomes, it is preferred that the actives are at least in part entrapped in the intravesicular space of the liposomes. Both actives are preferably water-soluble and thus preferably located in the aqueous phase of the liposomal formulations. Where the liposomes are multi-lamellar the actives may be between lamellae.
  • the composition is multivalent, that is it comprises several polysaccharide antigens in admixture.
  • the vaccine comprises two or more, preferably three or more, five or more, seven or more, for instance up to forty, preferably in the range 7 to 23.
  • the antigens are derived from the same bacterial species.
  • the antigens in such a multivalent composition may be co-encapsulated in liposomes, or there may be several populations, the liposomes of which each contain a separate antigen or antigen mixture distinct from the other populations.
  • the antigens are separately entrapped in liposomes, that there is a district popoulation for each polysaccharide antigen. This allows optimum flexibility in terms of generating a variety of different thereof vaccines from common starting-materials.
  • the protein carrier is the same in each of several populations.
  • the invention avoids such conjugation. This has the great advantage of allowing coformulation of many ingredients especially different antigens to form a multivalent antigen composition.
  • the protein carrier is non-toxic to a mammalian body and should preferably not stimulate an innate immune response when administered thereto.
  • the carrier is preferably effectively ‘inert’ in the mammalian body.
  • the protein acts as an adjuvant and is not biologically inert but engages (either directly, or via components that are released from killed host cells) host receptors to elicit cellular responses from the cells of the immune system in the form of an innate immune response.
  • the carrier protein has a molecular weight high enough for it to act as a T-cell dependent antigen.
  • the molecular weight is preferably at least 35 kDa, for instance up to 1000 kDa, eg in the range 75-400 kDa.
  • the present invention can use proteins which preferably have been used as carriers for T-cell independent antigens in the prior art, such as ovalbumin, tetanus toxoid and diphtheria toxoid.
  • the protein should generally be non-haemolytic, and non-toxic . In terms of non-toxicity, for instance, the protein should have an LD50 in excess of 4 mg/kg (in mice, iv or sc).
  • the protein should be level 6 on the Hodge & Sterner scale, ie be Relatively Harmless.
  • Suitable proteins include ovalbumin, tetanus toxoid, diphtheria toxoid and diphtheria CRM197 (a genetic mutant of diphtheria toxin).
  • Tetanus toxoid has a molecular weight of about 100 kDa.
  • Tetanus toxoid and diptheria CRM197 (a genetic mutant of the toxin) fail to elicit the significant immune response elicited by the corresponding toxins. This is thought to be due to attenuation by formaldehyde or genetic mutation. These carriers do, however, elicit an adaptive immune response by activation and the subsequent proliferation of T-helper cells that are needed for antibody responses.
  • the liposomal composition is in unit dosage form and comprises 1-30 ⁇ g of the protein carrier, more preferably 10-30 ⁇ g.
  • Such dosages are believed to be suitable for administration to a subject in need of immunisation, such as a human.
  • the polysaccharide antigens are all preferably derived from an infectious agent, preferably a pathogenic bacterium, for instance selected from Haemophilus influenzae, Streptococcus pneumoniae, Neisseria meningitidis, E. coli, or group B Streptococcus. Most preferably the antigens are derived from Haemophilus influenzae or Streptococcus pneumoniae.
  • the polysaccharide antigens are preferably T-cell independent antigens.
  • the weight ratio of polysaccharide antigen to protein carrier is preferably in the range 6:1 to 1:6, more preferably 4:1 to 1:3. Preferably, there is an excess of polysaccharide to protein in the composition.
  • the liposomes preferably comprise compounds having no overall ionic charge.
  • the compounds are preferably neutral, including zwitterionic compounds with one anionic and one cationic charge, but may contain small quantities of anionic or cationic compounds preferably being charge-balanced with oppositely charged compounds.
  • the compounds comprise phosphatidylcholine compounds and/or phosphatidylethanolamine compounds.
  • the liposome-forming compounds are usually amphiphilic, i.e. consist of a hydrophobic component and a hydrophilic component.
  • the hydrophobic components are generally provided by acyl chains but the liposome-forming compounds may alternatively be glycerol-ether based lipid compounds.
  • Non lipidic compounds that is not based on glycerol compounds, may be included if desired, for instance non-ionic surfactant type materials.
  • the compositions comprise cholesterol, for instance in a molar amount of at least 10%, preferably at least 25%, based on total liposome forming components.
  • the liposomes have an average diameter in the range 50-700 nm, more preferably 80-500 nm most preferably 100 to 300 nm.
  • the average diameter is measured as disclosed in WO99/65465, by photon correlation spectroscopy.
  • composition of the invention may be in the form of an aqueous suspension, that is in which the liposomes are suspended in a continuous aqueous medium.
  • the composition may be a precursor of such an aqueous composition, which may be diluted with water or an aqueous liquid to form the aqueous suspension.
  • Such precursors may be in the form of dried materials, especially in powder form, for instance provided by spray drying or freeze drying (lyophilisation).
  • compositions of the invention may be pharmaceutical compositions further comprising (a) pharmaceutically acceptable diluent(s) and/or excipient(s). Since the compositions are intended to be used directly or after intermediate formulation steps, to be administered to mammalian subjects, the diluents or the excipients are preferably pharmaceutically acceptable. Suitable excipients are known.
  • the composition comprises sugars.
  • Sugars may assist stabilisation of the liposomes during formation of the liposomes and/or in storage.
  • the liposomes are formed by the dehydration-rehydration method.
  • Empty small unilamellar vesicles (SUV's) e.g. made by hydrating a lipid film to form multi-lamellar vesicles and sonicating to form SUVs
  • active polysaccharide antigen and protein carrier
  • the dried product is then rehydrated and optionally subjected to steps to remove non-entrapped material, over-sized liposomes or to reduce the average liposome size, by methods known to the person skilled in the art.
  • the method used includes sugar in the suspending liquid of the dehydration step, as discussed in WO99/65465.
  • the sugar may be selected from monosaccharides such as glucose and fructose, disaccharides such as lactose and sucrose as well as polysaccharides.
  • a particularly preferred sugar is a di-saccharide such as trehalose, sucrose or lactose or a monosaccharide such as glucose.
  • the preferred sugar is sucrose.
  • the amount of sugar is such that mass ratio of sugar to liposome forming compound is in the range of from 1:1 to 6:1 w/w, most preferably from 1:1 to 5:1. With higher levels of sugar, the encapsulation efficiency of the method is reduced. With lower amounts of sugar, however, the control over the size of the final liposomes is lost.
  • the invention further provides a process for process for producing the new composition in which the polysaccaride antigen and protein carrier are co-encapsulated in liposomes.
  • the empty liposomes are preferably small or medium sized and may be multilamellar or unilamellar.
  • the product liposomes preferably have average diameter in the range 50 to 700 nm, more preferably in the range 80 to 500 nm, most preferably in the range 80 to 300 nm.
  • the composition contains very low levels of liposomes with diameters greater than 1500 nm, even more preferably very low levels of liposomes with diameters greater than 1000 nm.
  • the level of very small liposomes, e.g. less than 20 nm should also be kept as low as possible.
  • the invention also provides the use of the liposomes and compositions in the manufacture of a medicament for administration to a mammal to elicit an immune response to the polysaccharide antigen.
  • the immune response involves production of IgG at least, to the polysaccharide antigen, and additionally preferably IgM and IgA, preferably so that a protective effect to a challenge from the infectious micro organism is achieved in the recipient.
  • composition is administered subcutaneously, intravenously, intraperitoneally, intramuscularly, intranasally, by inhalation, intravaginally, buccally or orally. Most preferably the composition is administered subcutaneously.
  • the administration is for protective purposes to provide a response against infection by an infectious microbe, especially an infectious bacterium, of the type mentioned above.
  • the subject to which the composition is administered may be a mammal of any age, in need of having protective immunity.
  • the invention is of most value for treating humans.
  • administration may be to provide resistance to seasonal outbreaks, specific outbreaks of the infections, or may be part of health programmes especially for infants.
  • the invention is of particular value for the treatment of human infants having reduced immune responses to T-cell independent antigens, for instance polysaccharide antigens, for instance being less than two years of age.
  • the invention further provides methods of administering the compositions.
  • FIG. 1 shows the Anti PS (PRP) antibody response of mice when administered formulations ID1, ID2 & 3 and Act-Hib without cholesterol (Example 1);
  • FIG. 2 shows the Anti PS (PRP) antibody response of mice when adminstered formulations ID4, ID1, and Act-Hib with cholesterol (Example 1);
  • FIG. 3 shows the IgG antibody response pre and post immunisation to seven serotypes tested (Example 2).
  • the following liposome formulations (ID1-6) were prepared, Table 1, using a conventional lipid film dry/hydration to MLV/sonication to small unilamellar vesicles (SUV)/DRV process (WO9965465). Sucrose x3 lipid mass was added to the SUV and material(s) to be entrapped at the SUV stage prior to DRV process to reduce the size of the resultant liposomes formed post the DRV stage. The average diameter of the DRV by photon correlation spectroscopy is about 500 nm.
  • the lipidic materials Egg PC (EPC, 98% purity, Lipoid ) and Hydrogenated Soya PC (SPC-3.98% purity, Lipoid) were obtained form Lipoid GmbH. Whilst dioleoyloxyphosphatidylethanolamine (DOPE) (Avanti Product Number: 850725) were obtained form Avanti® Polar Lipids and, 1,2-dioleoyloxy-3-trimethylammonium propane (DOTAP) was obtained form Merck Chemicals Ltd. Purified polyribose ribitol phosphate capsular polysaccharide (PRP-PS) of Haemophilus influenzae type b and Tetanus Toxoid material were obtained from the Serum Institute of India (SII). The entrapment efficacies were also tested. The efficacy for both PS and protein for ID1 was around 90% or higher. The efficacy for ID4 for both materials was around 70%.
  • DOPE dioleoyloxyphosphatidylethanolamine
  • mice were dosed once subcutaneously with a) formulation ID1 or b) formulations ID2 and 3, mixed immediately prior to dosing.
  • PRP polyribose ribitol phosphate capsular polysaccharide
  • mice were dosed once subcutaneously with a) formulation ID4 or b) formulations ID1, mixed immediately prior to dosing.
  • PRP polyribose ribitol phosphate capsular polysaccharide
  • liposome formulations ID7-20 were prepared, Table 2, using a conventional lipid film dry/hydration to MLV/sonication to SUV/DRV process (i.e. as in Example 1). Sucrose x3 lipid mass (SUV) was added to the SUV and material(s) to be entrapped at the SUV stage prior to DRV process to reduce the size of the resultant liposomes formed post the DRV stage.
  • SUV Sucrose x3 lipid mass
  • the mutant form of diphtheria toxin is described and was isolated as Uchida, Jr., T., Pappenheimer, Jr., A. M., Greany, R., (1973) J. Biol. Chem. 248, 3838-3844. and Uchida, Jr., T., Pappenheimer, Jr., A. M., Harper, A. A., (1973) J. Biol. Chem. B 248, 3845-3850.
  • CRM197 is a non-toxic DT mutant containing a lesion in the A chain blocking ADP-ribosylation. CRM results from a base change in the structural gene resulting in the substitution of glutamic acid for glycine. While CRM shows no enzymatic activity, it is immunologically identical to diphtheria toxin. (Pappenheimer, Jr., A. M., Uchida, T. and Harper, A. A. (1972) Immunochem. 9, 891-906.)
  • CRM197 is similar to diphtheria toxoid.
  • CRM197 is a well defined protein in contrast to formaldehyde treated toxin (toxoid) which is non-specifically cross linked.
  • toxoid formaldehyde treated toxin
  • SDS gels the CRM197 protein migrates as a single major band of approximate molecular weight 63,000 daltons
  • the lipidic materials used were Egg PC (E PC, 0.98% purity, Lipiod) and cholesterol (Sigma). Pneumococcal capsular polysaccharide (Pn PS) equivalent to the American Type Culture Collection (ATCC).materials and diphtheria toxin CRM197 protein were obtained from the Serum Institute of India Limited (SIIL).
  • the liposomal mono PS entrapped formulations (ID7-20) were individually rehydrated (DRV process) and pooled together to make a multivalent formulation immediately before immunization, via subcutaneous injection, of five CD1 mice (female).
  • the dose of the multivalent vaccine contained the equivalent of 14 monovalent formulations containing 6 ⁇ g pneumococcal polysaccharide and 1.5 ⁇ g diphtheria toxin CRM197 protein and 0.559 mg of lipid. Consequently, the multivalent (14 serotypes) vaccine administered to the mice contain in total 84 ⁇ g pneumococcal polysaccharide and 21 ⁇ g diphtheria toxin CRM197 protein and 7.81 mg of lipid.
  • mice received a total of two immunisation doses 21 days apart, additionally sera samples via superficial tail vein sampling were taken from the mice prior to the first immunisation dose and 14 days after the second dose.
  • mice sera samples obtained were assayed for some of the Streptococcus pneumoniae antibodies, IgG (7 Serotypes: 4, 6B, 9V, 14, 18C (detects 33F responses), 19F and 23F), by multi-analyte fluorescent detection (Luminex).
  • IgG Serotypes: 4, 6B, 9V, 14, 18C (detects 33F responses), 19F and 23F
  • Luminex multi-analyte fluorescent detection
  • the Luminex multi-analyte fluorescent detection is based on microscopic beads (microspheres) internally labelled with two different fluorophores. When excited by a 635 nm laser, the fluorophores emit at different wavelengths, 658 nm and 712 nm. By varying the 658/712 emission ratios, an array of up to 100 different fluorescent profiles, called classifications, can be created. Using precision fluidics, digital signal processors, and advanced optics, the Luminex 100 analyser assigns each microsphere according to its predefined classification. Thus, multiple-bead classifications can be combined in a single sample.
  • each individual pneumococcal polysaccharide serotype is covalently attached to a microsphere with a unique classification.
  • all the different pneumococcal polysaccharide serotype microspheres are combined with a single dilution of test murine sample.
  • Antibodies in the murine sample attach to pneumococcal polysaccharide antigens on the microspheres.
  • the amount of antibody bound to the microspheres is determined with anti-mouse IgG conjugated to phycoerythrin. When excited at 532 nm, phycoerythrin emits at 575 nm.
  • the fluorescence intensity at 575 nm is directly proportional to the amount of antibody bound to the microspheres. Since the analyte specificity and position of each bead classification in the array is known, a single fluorescent reporter molecule can be used to calculate specific antibody levels to all serotypes tested (represented by the polysaccharide-bead conjugates).
  • FIG. 3 shows the calculated streptococcus pneumoniae antibodies, murine IgG (Serotypes specific responses: 4, 6B, 9V, 14, 18C (*see FIG. 3 , detects 33F responses), 19F and 23F), by multi-analyte fluorescent detection. Bars represent the average response of the 5 mice dosed and the error bars are standard deviations, the empty bars are pre immunisation background response of the mice whilst the solid bar is the response following the immunisation schedule.
  • the average response to all the seven serotypes tested were raised following immunisation with the blend (multivalent) of monoserotype liposomal compositions comprising of coentrapped pneumococcal polysaccharide and protein diphtheria toxin (197) CRM mutant within liposomes.
  • the increase in response, post immunisation, relative to the pre immunisation response was 1.8, 6.3, 1.4, 1.5, 2.5, 5.3 and 3.6 fold for the serotypes 4, 6B, 9V, 14, 33F, 19F and 23F fold respectively.
  • composition described demonstrates the ability to raise an antibody response to multivalent pneumococcal polysaccharide antigens in mice following immunisation with a blend (multivalent) of monoserotype liposomal compositions comprising coentrapped pneumococcal polysaccharide and protein diphtheria toxin (197) CRM mutant within liposomes.
  • liposome formulations were prepared, Table 3, using a conventional lipid film dry/hydration to MLV/sonication to SUV/DRV process (as in Example 1). Sucrose x3 lipid mass (SUV) was added to the SUV and material(s) to be entrapped at the SUV stage prior to DRV process to reduce the size of the resultant liposomes formed post the DRV stage.
  • SUV Sucrose x3 lipid mass
  • Each formulation (ID21-34), consisted of an individual pneumococcal polysaccharide serotype coentrapped with a protein Diphtheria Toxin CRM197 mutant within liposomes.
  • the lipidic materials used were Egg PC (E PC, 98% purity, Lipoid) and Cholesterol (Sigma).
  • Pneumococcal capsular polysaccharide (Pn PS) equivalent to the American Type Culture Collection (ATCC) materials and Diphtheria Toxin CRM197 protein were obtained from the Serum Institute of India Limited (SIIL).
  • the liposomal mono PS entrapped formulations (ID21-34) were individually rehydrated (DRV process) and pooled together to make a multivalent formulation immediately for immunisation, via subcutaneous injection, of ten Balb/C mice (female).
  • the dose of multivalent vaccine contained the equivalent of 14 monovalent formulations containing 0.2 ⁇ g Pneumococcal Polysaccharide and 0.48 ⁇ g Diphtheria Toxin CRM197 protein and 0.138 mg of lipid. Consequently, the multivalent (14 serotypes) vaccine administered to the mice contain in total 2.8 ⁇ g Pneumococcal Polysaccharide and 6.72 ⁇ g Diphtheria Toxin CRM1 97 protein and 1.935 mg of lipid.
  • mice Two groups of mice were immunised:
  • Group 1 were immunised, 14 day interval between doses, with 3 doses of the blend (multivalent) of monoserotype liposomal compositions, followed by pneumococcal polysaccharide vaccine (Pneumovax) boost administered 8 weeks after the last liposomal formulation dose.
  • Pneumovax pneumococcal polysaccharide vaccine
  • the Pneumovax dose administered consists of a mixture of highly purified capsular polysaccharides from 23 pneumococcal types of Streptococcus pneumoniae, serotypes (1 2 3 4 5 6B 7F 8 9N 9V 10A 11A12F 14 15B 17F 18C 19F 19A20 22F23 F & 33F).
  • the dose level administered for each purified capsular polysaccharides serotype was 7.5 ⁇ g and consequently the total polysaccharide dose administered was Pneumovax was 172.5 ⁇ g.
  • Group 2 were immunised, 14 day interval between doses, with 3 doses of pneumococcal polysaccharide vaccine (Pneumovax), followed by pneumococcal polysaccharide vaccine (Pneumovax) boost administered 8 weeks after the third Pneumovax dose.
  • Pneumovax pneumococcal polysaccharide vaccine
  • Pneumovax pneumococcal polysaccharide vaccine
  • mice Live Streptococcus pneumoniae challenge, was performed on all mice four weeks following the last dose. Briefly, mice were challenged intraperitoneally with 0.5 ml S. pneumoniae (serotype 6B) suspension prepared from fresh overnight colonies from a 5% horse blood agar plate were suspended in beef broth and further diluted to 4.0 ⁇ 10 7 CFU/ml.
  • S. pneumoniae serotype 6B
  • mice were observed for 6 days following administration of the bacterial challenge, and scored 0-4 based on their behaviour and clinical signs as below.
  • Score 1 minor clinical signs of infection and inflammation e.g. observations of minor sign of distress and pain, changed activity, and social withdrawal.
  • Score 2 sever signs of infection like stiff movements, lack of curiosity, forced ventilation, changed body position, piloerection in the skin, or changes in movement.
  • Score 3 sever pain and the mouse was sacrificed immediately to minimise the suffering of the animal.
  • mice are better protected against live Streptococcus pneumoniae challenge (serotype 6B), following immunisation of a blend (multivalent) of monoserotype liposomal compositions comprising of coentrapped pneumococcal polysaccharide and protein Diphtheria Toxin (197)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
US12/088,656 2005-09-30 2006-09-29 Multivalent liposomal vaccine compositions comprising polysaccharide antigens and a protein adjuvant Abandoned US20090068254A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05256160 2005-09-30
EP05256160.2 2005-09-30
PCT/EP2006/066938 WO2007039584A1 (fr) 2005-09-30 2006-09-29 Compositions vaccinales liposomales multivalentes comprenant des antigenes polysaccharides et un adjuvant proteique

Publications (1)

Publication Number Publication Date
US20090068254A1 true US20090068254A1 (en) 2009-03-12

Family

ID=35841928

Family Applications (3)

Application Number Title Priority Date Filing Date
US12/088,656 Abandoned US20090068254A1 (en) 2005-09-30 2006-09-29 Multivalent liposomal vaccine compositions comprising polysaccharide antigens and a protein adjuvant
US12/088,672 Expired - Fee Related US8753647B2 (en) 2005-09-30 2006-09-29 Liposomal vaccine compositions comprising a polysaccharide antigen and a protein adjuvant
US14/272,313 Active US9750692B2 (en) 2005-09-30 2014-05-07 Liposomal vaccine compositions comprising a polysaccharide antigen and a protein adjuvant

Family Applications After (2)

Application Number Title Priority Date Filing Date
US12/088,672 Expired - Fee Related US8753647B2 (en) 2005-09-30 2006-09-29 Liposomal vaccine compositions comprising a polysaccharide antigen and a protein adjuvant
US14/272,313 Active US9750692B2 (en) 2005-09-30 2014-05-07 Liposomal vaccine compositions comprising a polysaccharide antigen and a protein adjuvant

Country Status (6)

Country Link
US (3) US20090068254A1 (fr)
EP (2) EP1928418B1 (fr)
JP (2) JP2009510032A (fr)
AT (1) ATE537813T1 (fr)
ES (1) ES2374648T3 (fr)
WO (2) WO2007039584A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11491215B2 (en) * 2018-05-24 2022-11-08 Lawrence Livermore National Security, Llc Antigenic combinations against Francisella bacteria and related nanolipoprotein particles, compositions, methods and systems

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010104883A1 (fr) * 2009-03-09 2010-09-16 Molecular Express, Inc. Procédés et compositions pour formulation liposomale d'antigènes et leurs utilisations
KR20110068831A (ko) 2009-12-16 2011-06-22 재단법인 전라남도생물산업진흥재단 리포좀 조성물, 그 제조방법, 및 폐렴 백신으로서의 그 용도
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
MX2020007246A (es) * 2017-10-13 2020-11-13 Univ New York State Res Found Diseño de vacuna integral para el avance de enfermedad comensal.
WO2020115171A1 (fr) 2018-12-06 2020-06-11 Glaxosmithkline Biologicals Sa Compositions immunogènes

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4686102A (en) * 1984-04-12 1987-08-11 American Cyanamid Company Multivalent pneumococcal vaccine and preparation thereof
AU648509B2 (en) * 1989-07-14 1994-04-28 Wyeth Holdings Corporation Stable vaccine compositions containing interleukins
IE912535A1 (en) 1990-07-27 1992-01-29 Res Dev Foundation Liposomes that Provide Thymic Dependent Help to Weak Vaccine¹Antigens
WO1992020370A1 (fr) 1991-05-13 1992-11-26 Regents Of The University Of California Vaccins comprenant un polysaccharide encapsule dans un liposome
BR9811475A (pt) * 1997-07-17 2000-08-15 North American Vaccine Inc Conjugados imunogênicos compreendendo uma porina meningocóccica de grupo b e um polissacarìdeo de h. influenzae
AU1208499A (en) * 1997-10-31 1999-05-24 Cistron Biotechnology, Inc. Encapsulated immunomodulators useful as vaccine adjuvants
GB9813100D0 (en) 1998-06-18 1998-08-19 Secr Defence Method of forming liposomes
GB0225736D0 (en) * 2002-11-05 2002-12-11 Adjuvantix Ltd T-Cell Independent Vaccine
EP1550458A1 (fr) * 2003-12-23 2005-07-06 Vectron Therapeutics AG Adjuvants liposomals synergiques

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11491215B2 (en) * 2018-05-24 2022-11-08 Lawrence Livermore National Security, Llc Antigenic combinations against Francisella bacteria and related nanolipoprotein particles, compositions, methods and systems

Also Published As

Publication number Publication date
US8753647B2 (en) 2014-06-17
JP5279497B2 (ja) 2013-09-04
US20080317838A1 (en) 2008-12-25
US9750692B2 (en) 2017-09-05
JP2009510032A (ja) 2009-03-12
WO2007039584A1 (fr) 2007-04-12
EP1928419A1 (fr) 2008-06-11
WO2007039583A1 (fr) 2007-04-12
ES2374648T3 (es) 2012-02-20
EP1928418B1 (fr) 2011-12-21
ATE537813T1 (de) 2012-01-15
JP2009510031A (ja) 2009-03-12
EP1928418A1 (fr) 2008-06-11
US20140248337A1 (en) 2014-09-04

Similar Documents

Publication Publication Date Title
US9750692B2 (en) Liposomal vaccine compositions comprising a polysaccharide antigen and a protein adjuvant
De Serrano et al. Liposomal vaccine formulations as prophylactic agents: design considerations for modern vaccines
Chatzikleanthous et al. Lipid-based nanoparticles for delivery of vaccine adjuvants and antigens: toward multicomponent vaccines
JP6625587B2 (ja) Ｔｌｒ２を活性化するか、またはその活性を増加させるアジュバントを含むリポソーム組成物およびその使用
Bernasconi et al. Mucosal vaccine development based on liposome technology
Li et al. Enhanced immune response to T-independent antigen by using CpG oligodeoxynucleotides encapsulated in liposomes
DE60310562T2 (de) Verfahren zur verstärkung einer immunantwort von nukleinsäureimpfungen
KR20010033613A (ko) 보조제 첨가된 백신 제형
JP2014528955A5 (fr)
MX2008012405A (es) Composicion inmunogenica.
CN102202689A (zh) 疫苗
Glück Liposomal presentation of antigens for human vaccines
ES2369550T3 (es) Formulación de adyuvante para administración en mucosas.
JP2005525992A (ja) 生物学的物質を充填した小胞の調製法およびそれらの様々な使用
JPH06504759A (ja) リポソーム含有ワクチン組成物
JPH04210925A (ja) 鼻腔内または吸入投与用ワクチン製剤およびその製造方法
MX2010011393A (es) Vacuna.
EP1150713B1 (fr) Formulation de vaccin contenant des monogycerides ou des acides gras comme adjuvant
Sachetelli et al. Evaluation of the pulmonary and systemic immunogenicity of fluidosomes, a fluid liposomal–tobramycin formulation for the treatment of chronic infections in lungs
EP2514410B1 (fr) Composition liposomale, son procédé de préparation et utilisation de cette composition comme vaccin contre la pneumonie
Myschik et al. Advances in lipid-based subunit vaccine formulations
Mirchamsy et al. Stimulating role of toxoids-laden liposomes in oral immunization against diphtheria and tetanus infections
Ariaee et al. Mucosal adjuvant potential of Quillaja saponins and cross-linked dextran microspheres, co-administered with liposomes encapsulated with tetanus toxoid
Hook et al. Immune stimulating complexes (ISCOMs) and Quil-A containing particulate formulations as vaccine delivery systems
Patel et al. Cationic nanoparticles for delivery of CpG oligodeoxynucleotide and ovalbumin: In vitro and in vivo assessment

Legal Events

Date Code Title Description
AS Assignment

Owner name: LIPOXEN TECHNOLOGIES LIMITED, UNITED KINGDOM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BACON, ANDREW DAVID;GREGORIADIS, GREGORY;LAING, PETER;REEL/FRAME:021384/0199

Effective date: 20080520

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION